You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》贝康医疗(02170.HK)公开超购近402倍及上限定价 一手中签率10%
阿思达克 02-05 08:48
贝康医疗(02170.HK)公布招股结果,发行6,666.7万股,原计划10%为本地公开发售,公开发售录超购401.8倍,经重新分配後,公开发售股数增至50%,国际发售项下初步提呈发售的发售股份已获大幅超额认购,相当於可供认购H股总数的约21.8倍。

每股发售价定於27.36元,为上限定价(招股价每股26.36至27.36元),一手500股中签率为10%,认购200手(10万股)才可稳获一手。该股将於下周一(8日)上市,中信里昂证券为独家保荐人。

公司预计,发售所得款项净额约为17.17亿元,当中约30%用於核心产品PGT-A试剂盒;约20%用於PGT-M试剂盒的临床试验、注册申报及商业化;30%将用於开发其他产品;约10%将用提升研发能力;余下约10%为一般营运资金。

公司是次招股引入7名基石投资者,包括清池资本、奥博资本、CRF Investment、Affin Hwang Capital、WinTwin Capital、睿远基金及常春藤资产管理,合共认购2,550.25万股股份,占紧随全球发售完成後公司已发行股本的约9.6%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account